HIsTological and CLinical effects of Imipramine in the treatment of patients with cancer over-expressing Fascin1. (HITCLIF)
Key facts
- Where
- Cartagena és Murcia, SpanyolországSee the 3 sites
- Phase
- 2. fázis
Where in Spanyolország
- General University Hospital Santa LuciaCartagena, SpanyolországTaking people
- Hospital General Universitario Morales MeseguerMurcia, SpanyolországTaking people
- University Clinical Hospital Virgen De La ArrixacaMurcia, SpanyolországTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Fundacion Para La Formacion E Investigacion Sanitaria De La Region De Murcia
- Trial code
- EU 2023-504943-15-00
- Record updated
- 2025. június 13.
- Original description
To assess whether treatment with Tofranil© produces significant changes in the histological and molecular manifestations of the epithelial-mesenchymal transition (EMT) in the period from tumor diagnosis by biopsy to surgical resection.Read full original descriptionShow less
To assess whether treatment with Tofranil© produces significant changes in the histological and molecular manifestations of the epithelial-mesenchymal transition (EMT) in the period from tumor diagnosis by biopsy to surgical resection.
The evaluation of the Main Objective will be carried out in the histological examination of the tumor piece product of the surgical resection; usually at 2-6 weeks for group A and between 3-6 months for neoadjuvant patients (group B).
Inclusion: Resectable tumor; Obtaining Written Informed Consent; Diagnosis of colon, rectal or triple negative breast cancer by biopsy; Overexpression of fascina1 in primary tumor; Patient over 18 years of age.
Exclusion: Patient on current treatment with SSRIs, SNRIs, MAOIs, tramadol or trazadone or within the 14 days prior to recruitment; Metastatic disease at diagnosis or not candidates for neoadjuvant therapy; Colorectal cancer with clinical symptoms of sub-obstruction or obstruction; Known diagnosis of major depressive disorder, bipolar depression, or psychosis; Suspected inability to comply with treatment adequately or conditions that limit its reliability (psychiatric illness, drug addiction, etc.); History of heart disease; Severe renal failure (GFR <30 mL/min); Hepatic failure or bilirubin > 2 mg/dl; Woman of childbearing age who refuses to use any contraceptive method; ECOG scale 3 or 4.